Albuterol Use in Children Hospitalized with Human Metapneumovirus Respiratory Infection
Introduction. Human metapneumovirus (HMPV) is a paramyxovirus from the same subfamily as respiratory syncytial virus (RSV) and causes similar acute lower respiratory tract infection. Albuterol in the setting of acute RSV infection is controversial and has not yet been studied in HMPV. We sought to d...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | International Journal of Pediatrics |
| Online Access: | http://dx.doi.org/10.1155/2016/7021943 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849685625662341120 |
|---|---|
| author | Lindsey K. Rasmussen Jennifer Schuette Michael C. Spaeder |
| author_facet | Lindsey K. Rasmussen Jennifer Schuette Michael C. Spaeder |
| author_sort | Lindsey K. Rasmussen |
| collection | DOAJ |
| description | Introduction. Human metapneumovirus (HMPV) is a paramyxovirus from the same subfamily as respiratory syncytial virus (RSV) and causes similar acute lower respiratory tract infection. Albuterol in the setting of acute RSV infection is controversial and has not yet been studied in HMPV. We sought to determine the frequency of albuterol use in HMPV infection and the association between albuterol administration and patient outcomes. Methods. We conducted a retrospective cohort study identifying all patients hospitalized in a tertiary care children’s hospital with laboratory-confirmed HMPV infection between January 2010 and December 2010. Results. There were 207 patients included in the study; 57% had a chronic medical condition. The median hospital length of stay was 3 days. Only 31% of patients in the study had a documented wheezing history, while 69% of patients received at least one albuterol treatment. There was no difference in length of stay between patients who received albuterol and those who did not. Conclusion. There is a high frequency of albuterol use in children hospitalized with HMPV infection. As with RSV, evidence may not support routine use of bronchodilators in patients with acute HMPV respiratory infection. Research involving additional patient outcomes and illness severity indicators would be useful in future studies. |
| format | Article |
| id | doaj-art-c43d2b5de4484c00b2d5eb3db2169c8c |
| institution | DOAJ |
| issn | 1687-9740 1687-9759 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Pediatrics |
| spelling | doaj-art-c43d2b5de4484c00b2d5eb3db2169c8c2025-08-20T03:23:03ZengWileyInternational Journal of Pediatrics1687-97401687-97592016-01-01201610.1155/2016/70219437021943Albuterol Use in Children Hospitalized with Human Metapneumovirus Respiratory InfectionLindsey K. Rasmussen0Jennifer Schuette1Michael C. Spaeder2Division of Pediatric Anesthesiology and Critical Care Medicine, The Johns Hopkins Medical Institutions, 1800 Orleans Street, Baltimore, MD 21287, USADivision of Pediatric Anesthesiology and Critical Care Medicine, The Johns Hopkins Medical Institutions, 1800 Orleans Street, Baltimore, MD 21287, USADivision of Pediatric Critical Care, University of Virginia School of Medicine, P.O. Box 800386, Charlottesville, VA 22908, USAIntroduction. Human metapneumovirus (HMPV) is a paramyxovirus from the same subfamily as respiratory syncytial virus (RSV) and causes similar acute lower respiratory tract infection. Albuterol in the setting of acute RSV infection is controversial and has not yet been studied in HMPV. We sought to determine the frequency of albuterol use in HMPV infection and the association between albuterol administration and patient outcomes. Methods. We conducted a retrospective cohort study identifying all patients hospitalized in a tertiary care children’s hospital with laboratory-confirmed HMPV infection between January 2010 and December 2010. Results. There were 207 patients included in the study; 57% had a chronic medical condition. The median hospital length of stay was 3 days. Only 31% of patients in the study had a documented wheezing history, while 69% of patients received at least one albuterol treatment. There was no difference in length of stay between patients who received albuterol and those who did not. Conclusion. There is a high frequency of albuterol use in children hospitalized with HMPV infection. As with RSV, evidence may not support routine use of bronchodilators in patients with acute HMPV respiratory infection. Research involving additional patient outcomes and illness severity indicators would be useful in future studies.http://dx.doi.org/10.1155/2016/7021943 |
| spellingShingle | Lindsey K. Rasmussen Jennifer Schuette Michael C. Spaeder Albuterol Use in Children Hospitalized with Human Metapneumovirus Respiratory Infection International Journal of Pediatrics |
| title | Albuterol Use in Children Hospitalized with Human Metapneumovirus Respiratory Infection |
| title_full | Albuterol Use in Children Hospitalized with Human Metapneumovirus Respiratory Infection |
| title_fullStr | Albuterol Use in Children Hospitalized with Human Metapneumovirus Respiratory Infection |
| title_full_unstemmed | Albuterol Use in Children Hospitalized with Human Metapneumovirus Respiratory Infection |
| title_short | Albuterol Use in Children Hospitalized with Human Metapneumovirus Respiratory Infection |
| title_sort | albuterol use in children hospitalized with human metapneumovirus respiratory infection |
| url | http://dx.doi.org/10.1155/2016/7021943 |
| work_keys_str_mv | AT lindseykrasmussen albuteroluseinchildrenhospitalizedwithhumanmetapneumovirusrespiratoryinfection AT jenniferschuette albuteroluseinchildrenhospitalizedwithhumanmetapneumovirusrespiratoryinfection AT michaelcspaeder albuteroluseinchildrenhospitalizedwithhumanmetapneumovirusrespiratoryinfection |